ERA-EDTA recommendation on the use of tolvaptan in polycystic kidney disease

The ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice have published a position statement on the use of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD).


ADPKD is the most common hereditary kidney disorder, accounting for -10% of European patients on dialysis or living with a renal transplant. Approximately 70% of patients with ADPKD progress to end-stage renal disease (ESRD) at a median age of 58 years.


Read more